Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Impact of an Intensified Thromboprofylaxis Protocol in COVID-19

16 de mayo de 2020 actualizado por: Jessa Hospital

Impact of Implementation of an Intensified Thromboprofylaxis Protocol in in Critically Ill ICU Patients With COVID-19: a Longitudinal Controlled Before-after Study

The aim of this study is to investigate and compare the mortality, the incidence of DVT and the incidence of kidney and liver failure in patients admitted to the ICU before and after the implementation of an intensified thromboprofylaxis protocol on 31st of March 2020. Patients in the before group are admitted at the ICU from 13/3/2020-30/3/2020 and patients in the after group are admitted to the ICU from 31/3 until 20/4/2020.

Descripción general del estudio

Estado

Terminado

Descripción detallada

Background Patients admitted to the Intensive Care Unit (ICU) are known to be at risk for thrombo-embolic events. Virchow's triad describes the major risk factors in three categories: venous stasis, vessel injury and activation of blood coagulation. A prolonged mechanical ventilation together with the hemodynamic effects of this ventilation with a high positive and expiratory pressure (PEEP), the presence of central venous catheters, the immobilization of these patients and the presence of obesity or other comorbidities can attribute to the occurrence of a deep venous thrombosis (DVT) in patients admitted at ICU. The incidence of DVT during ICU stay has been reported between 5 and 15%.

On the 13th of March, the first COVID-19 patient was admitted at the ICU at the Jessa Hospital. Within a few days, the admissions at our COVID-19 unit grew exponential. In these difficult time, research concerning COVID-19 has been performed indicating the COVID-19 virus induces a hyper-inflammatory state. It has been suggested that systemic inflammation induces endothelial injury. This will activate the coagulation cascade and impair fibrinolysis with disruption of endothelial barrier, and loss of physiologic antithrombotic factors which may elevated the risk for DVTs significantly. Up to now, there is still no causal treatment for COVID-19. The current management of COVID-19 is mainly supportive i.e. a prolonged inflammatory status and a prolonged risk for VTE.

We have shown in a previous cross sectional study that the prevalence of deep venous thrombosis (DVT) in critically ill ICU patients with COVID-19 treated with a prophylactic dose of low molecular weight heparin (LMWH) is more than 60% (submitted manuscript). Consequently, the risk of VTE complications in this patient group is very high. In the light of these findings, an intensified thromboprofylaxis protocol was applied in critically ill ICU patients with COVID-19 at our ICU units since 31st of March 2020.

Aim The aim of this study is to investigate and compare the mortality, the incidence of DVT and the incidence of kidney and liver failure in patients admitted to the ICU before and after the implementation of an intensified thromboprofylaxis protocol on 31st of March 2020. Patients in the before group are admitted at the ICU from 13/3/2020-30/3/2020 and patients in the after group are admitted to the ICU from 31/3 until 20/4/2020.

Design This is a retrospective, longitudinal, before-after controlled study investigating the mortality, the incidence of DVT and the incidence of kidney and liver failure in COVID-19 patients admitted to the ICU before and after the implementation of an intensified thromboprofylaxis protocol.

Outcome measures The primary endpoint of this retrospective study is to investigate the mortality in critically ill ICU patients before and after the implementation of the intensified thromboprofylaxis protocol in our hospital.

Secondary endpoints are the incidence of DVTs with the number and locations of these thromboses, the incidence of kidney failure and the incidence of liver failure in COVID-19 patients admitted to the ICU before and after the implementation of the thromboprofylaxis protocol.

Additional data collection

Additional collected parameters are listed below and are collected as a standard-of-care in our hospital:

  • Demographics: i.e age, gender, BMI, Apache II score (to predict mortality)
  • Comorbidities: smoking, obesity, hypertension, diabetes, cardiovascular disease, respiratory disease, malignancies, renal failure (AKI), liver failure, gastrointestinal disease, neurological conditions, mental state, other
  • Symptoms at the time of admission to ICU: i.e fever, body temperature, dyspnoea, headache, diarrhea etc…
  • Laboratory results of all standard parameters measured
  • Treatment: antiviral agents, antibiotics, etc…
  • Complications: shock, heart failure, sepsis, stroke, etc…
  • Ventilation: method, PEEP, FiO2, P/F ratio ..
  • SOFA score (Sequential Organ Failure Assessment)
  • Radiological findings: pneumonia, ground-glass opacity..

Tipo de estudio

De observación

Inscripción (Actual)

72

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

      • Hasselt, Bélgica, 3500
        • Jessa Hospital

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

N/A

Géneros elegibles para el estudio

Todos

Método de muestreo

Muestra de probabilidad

Población de estudio

All adult COVID19+ patients admitted to the ICU from 13th of March until 20th of April 2020.

Descripción

Inclusion Criteria:

- All adult COVID19+ patients admitted to the ICU from 13th of March until 20th of April 2020.

Exclusion Criteria:

- Patients younger than 18 years old.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

Cohortes e Intervenciones

Grupo / Cohorte
Intervención / Tratamiento
Before or control group
All patients admitted to ICU from March 13th 2020 until March 30th 2020 received routine low dose pharmacological VTE prophylaxis
This protocol contains a routine low dose pharmacological venous thromboembolism (VTE) prophylaxis with LMWH
After or intervention group
On March 31th 2020 an individualised, more aggressive thromboprophylaxis protocol was implemented. This individualised protocol contains three cornerstones: an increase in dosage of prophylactic LMWH close to therapeutic doses, introduction of routine venous ultrasonography and daily measurements of plasma anti-factor Xa activity
This individualised protocol contains three cornerstones: an increase in dosage of prophylactic LMWH close to therapeutic doses, introduction of routine venous ultrasonography and daily measurements of plasma anti-factor Xa activity

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
2 week mortality
Periodo de tiempo: 2 weeks after admission at ICU
mortality was assessed in all COVID 19 patients admitted to the ICU
2 weeks after admission at ICU

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
incidence of venous thromboembolism
Periodo de tiempo: during ICU stay up till 3th of May 2020
the incidence of venous thromboembolism was evaluated in all COVID 19 patients admitted to the ICU
during ICU stay up till 3th of May 2020
1 week mortality
Periodo de tiempo: 1 week after admission at ICU
mortality was assessed in all COVID 19 patients admitted to the ICU
1 week after admission at ICU
3 week mortality
Periodo de tiempo: 3 weeks after admission at ICU
mortality was assessed in all COVID 19 patients admitted to the ICU
3 weeks after admission at ICU
1 month mortality
Periodo de tiempo: 1 month after admission at ICU
mortality was assessed in all COVID 19 patients admitted to the ICU
1 month after admission at ICU
incidence of kidney failure
Periodo de tiempo: during ICU stay up till 3th of May 2020
incidence of acute kidney failure in all COVID 19 patients admitted to the ICU
during ICU stay up till 3th of May 2020
incidence of continuous renal replacement therapy (CRRT)
Periodo de tiempo: during ICU stay up till 3th of May 2020
incidence of continuous renal replacement therapy (CRRT) in all COVID 19 patients admitted to the ICU
during ICU stay up till 3th of May 2020
lowest PaO2/FiO2 (P/F) ratio
Periodo de tiempo: during ICU stay up till 3th of May 2020
evaluation of the lowest P/F ratio in all COVID 19 patients admitted to the ICU
during ICU stay up till 3th of May 2020
highest Sequential Organ Failure Assessment (SOFA) score
Periodo de tiempo: during ICU stay up till 3th of May 2020
evaluation of the highest SOFA score in all COVID 19 patients admitted to the ICU
during ICU stay up till 3th of May 2020
length of stay
Periodo de tiempo: during ICU and hospital stay up till 3th of May 2020
evaluation of the length of stay in ICU and hospital of all COVID 19 patients admitted to the ICU
during ICU and hospital stay up till 3th of May 2020
highest bilirubin
Periodo de tiempo: during ICU stay up till 3th of May 2020
evaluation of the highest bilirubine level in all COVID 19 patients admitted to the ICU
during ICU stay up till 3th of May 2020
highest ( AST
Periodo de tiempo: during ICU stay up till 3th of May 2020
evaluation of the highest AST level in all COVID 19 patients admitted to the ICU
during ICU stay up till 3th of May 2020
highest Aspartaat-Amino-Transferase (ALT)
Periodo de tiempo: during ICU stay up till 3th of May 2020
evaluation of the highest ALT level in all COVID 19 patients admitted to the ICU
during ICU stay up till 3th of May 2020

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

4 de mayo de 2020

Finalización primaria (Actual)

15 de mayo de 2020

Finalización del estudio (Actual)

15 de mayo de 2020

Fechas de registro del estudio

Enviado por primera vez

16 de mayo de 2020

Primero enviado que cumplió con los criterios de control de calidad

16 de mayo de 2020

Publicado por primera vez (Actual)

19 de mayo de 2020

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

19 de mayo de 2020

Última actualización enviada que cumplió con los criterios de control de calidad

16 de mayo de 2020

Última verificación

1 de mayo de 2020

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Ensayos clínicos sobre standard protocol

3
Suscribir